奎硫平与氟哌啶醇治疗首发女性精神分裂症对照研究

A control study of quetiapine vs. haloperidol in the treatment of first-episode female schizophrenia

目的探讨奎硫乎治疗首发女性精神分裂症的临床疗效及安全性。方法将60例女性精神分裂症患者随机分为两组，每组30例，研究组口服奎硫平治疗，对照组口服氟哌啶醇治疗，观察54w。于治疗前及治疗2w、4w、8w、54w末采用阳性与阴性症状评定量表评定临床疗效、副反应量表评定不良反应。结果治疗8w末研究组有效率93．3％，对照组为90．0％；54w末分别为100％和81．48％，研究组有效率显著高于对照组（P〈0．01）。治疗2w末起两组阳性与阴性症状量表评分均较治疗前下降显著（P〈0．01），治疗54w末研究组较对照组下降更显著（P〈0．01）。治疗8w末研究组肌强直、静坐不能、视力模糊、吞咽困难、口干、失眠、便秘、血清催乳素升高等不良反应发生率均显著低于对照组（P〈0．05或0．01）。结论奎硫平能显著改善女性精神分裂症患者的阳性与阴性症状，且安全性高，依从性好。

Objective To explore the clinical efficacy and safety of quetiapine in the treatment of female first-episode schizophrenia. Methods Sixty female schizophrenics were randomly assigned to two groups of 30 ones each, resaerc group took orally quetiapine and control group did haloperidol for 54 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale（PANSS） and adverse reactions with the Treatmnet Emergent Symtom Scale（TESS） before treatment and at the ends of the 2^nd ,4^th,8^th and 54^th week treatment. Results Effective rates of the research and control group were respectively 93.3% and 90.0% at the end of the 8^th week and 100% and 81.48% at the end of the 54^th. Effective rate was significantly higher in the research than in the control group（P〈0.01）. Since the end of the 2nd week, scores of the PANSS of both groups lowered more significantly compared with pretreatment（P〈0.01） ;but at the end of the 54^th week the PANSS score lowered more signifcantly in the research than in the control group（P〈0.01）. Incidences of such adverse reactions as myotonia, akathisia, blurred vision, dysphagia, dry mouth, insomnia, constipation and serum prolactin elevation were all significantly lowere in the research than in the control group（P〈0.05 or 0.01）. Conclusion Quetiapine can significantly improve positive and negative symptoms of female schizophrenics, has higher safety and better compliance.